-
EYPT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
EyePoint Pharmaceuticals (EYPT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm |
Cash burn (monthly) | 3.65 mm | 4.43 mm | 10.92 mm | 9.75 mm | 13.01 mm | 9.46 mm |
Cash used (since last report) | 16.91 mm | 20.56 mm | 50.61 mm | 45.19 mm | 60.32 mm | 43.85 mm |
Cash remaining | 63.07 mm | 59.42 mm | 29.37 mm | 34.79 mm | 19.66 mm | 36.13 mm |
Runway (months of cash) | 17.3 | 13.4 | 2.7 | 3.6 | 1.5 | 3.8 |
13F holders | Current |
---|---|
Total holders | 141 |
Opened positions | 21 |
Closed positions | 36 |
Increased positions | 47 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 442.83 bn |
Total shares | 67.59 mm |
Total puts | 262.80 k |
Total calls | 176.80 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 8.32 mm | $66.52 bn |
Suvretta Capital Management | 5.18 mm | $41.35 bn |
BlackRock | 4.16 mm | $33.20 bn |
BEN Franklin Resources | 4.01 mm | $40.80 bn |
Adage Capital Partners GP, L.L.C. | 3.79 mm | $30.29 bn |
Adage Capital Management | 3.79 mm | $43.45 mm |
Vanguard | 3.05 mm | $24.35 bn |
Therapeutics OcuMension | 3.01 mm | $19.81 mm |
T. Rowe Price | 2.49 mm | $19.91 mm |
EW Healthcare Partners | 2.34 mm | $42.88 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 25 | George Elston | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,834 | 0.00 | 75,550 |
9 Feb 25 | George Elston | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,834 | 0.00 | 0 |
9 Feb 25 | Nancy Lurker | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,000 | 0.00 | 205,436 |
9 Feb 25 | Nancy Lurker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 20,000 | 0.00 | 0 |
9 Feb 25 | Jay S. Duker | Common Stock | Payment of exercise | Dispose F | No | No | 6.495 | 2,055 | 13.35 k | 77,651 |
9 Feb 25 | Jay S. Duker | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,000 | 0.00 | 79,706 |
9 Feb 25 | Jay S. Duker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,000 | 0.00 | 0 |
8 Jan 25 | Reginald J. Sanders | Stock Options Common Stock | Grant | Acquire A | No | No | 9.11 | 80,000 | 728.80 k | 80,000 |